Susan Altschuller is recorded as Chief Accounting Officer at Climb Bio, Inc. (CLYM) since April 30, 2026 and CFO at Climb Bio, Inc. (CLYM). The newest filing on record that lists Susan Altschuller as CFO at Climb Bio, Inc. (CLYM) is dated April 24, 2026. Climb Bio, Inc. reported in an 8-K filed April 3, 2026 that Susan Altschuller was appointed principal accounting officer, effective April 30, 2026. The proxy statement of Climb Bio, Inc. reports total compensation of $1,151,372 for Susan Altschuller in fiscal 2025, including a base salary of $127,500. Susan Altschuller has spoken on 4 investor events across 1 company, most recently for Climb Bio, Inc. on September 16, 2026. Climb Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Climb Bio, Inc. includes Aoife Brennan (CEO, CFO and Board Member), Aoife Brennan, M.B., Ch.B. (CEO and Board Member), Dr. Stephen Thomas (CEO) and 7 others.
“As a result of Ms. Driscoll's separation, Dr. Altschuller, the Company's Chief Financial Officer and principal financial officer, will also serve as the Company's principal accounting officer, effective as of the Separation Date.”
Climb Bio, Inc. Form 8-K, filed April 3, 2026
· Read the filing
Susan Altschuller on recent calls
“So the technology, the sweeper technology, as we call it, it's the technology that I was most familiar with from, you know, Soliris to Ultimeris, and it's pH-dependent binding to APRIL.”
“We have two antibody approaches in renal disease and other autoimmune diseases. Our lead program is our CD19 monoclonal antibody, Budoprutug. Prutug, and that is in development in phase 2 for PMN, in phase 1b for ITP and SLE, and we can go through the cadence of readouts there.”
“So I think first we look at safety and I think, you know, April has been, you know, very good safety tolerability profile. So I think, you know, we expect no issues there.”
“And what started with Voodoo-Krutag, our CD19 naked monoclonal antibody, that asset had generated in my patients of data some very compelling complete B-cell depletion, autoantibody, seronegativity, and proteinuria, 60% complete renal response.”
